吴瑶;余珊;段杰;王芊入;吴倪;李波;姜黎;

• 1:成都市郫都区人民医院药学部

摘要(Abstract)：

根据《中国心血管病报告》,中国现患心血管病人数约2.9亿,而大量循证医学证据证实了血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)治疗心血管等疾病的价值。ACEI/ARB是肾素-血管紧张素-醛固酮系统(RAAS)的阻滞剂,可上调血管紧张素转换酶2(ACE2)表达水平。而ACE2是新型冠状病毒肺炎(COVID-19)发生发展的关键分子靶点,一方面它是侵入人体细胞的必须受体,触发了COVID-19的发生,另一方面在COVID-19的发展过程中发挥抗炎保护作用。本文探讨在疫情防控期间能否使用ACEI/ARB,以期为心血管疾病患者合理使用ACEI/ARB提供思路与参考。

关键词(KeyWords)： 新型冠状病毒肺炎;新型冠状病毒;血管紧张素转化酶2;血管紧张素转换酶抑制剂;血管紧张素受体拮抗剂;心血管疾病;肾素-血管紧张素-醛固酮系统

Abstract:

Keywords:

基金项目(Foundation): 四川医事卫生法治研究中心资助项目(YF19-Q14);; 成都市郫都区人民医院新型冠状病毒肺炎院内课题(2020XG01)

作者(Author): 吴瑶;余珊;段杰;王芊入;吴倪;李波;姜黎;

Email:

DOI: 10.14053/j.cnki.ppcr.202101001

参考文献(References)：

• [1] 中华人民共和国国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第七版)[J].中国医药,2020,15(6):801-805.
• [2] Wan Y,Shang J,Graham R,et al.Receptor recognition by novel coronavirus from Wuhan:an analysis based on decade-long structural studies of SARS[J].J Virol,2020.pii:JVI.00127-20.[Epub ahead of print].
• [3] Zhou P,Yang XL,Wang XG,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020.
• [4] Lu R,Zhao X,li J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,10224(395):565-574.
• [5] Xu X,Chen P,Wang J,et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J].Science China Life Sciences,2020:1-4.
• [6] Hui DS,Azhar EI,Madani TA,et al.The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan,China[J].Intl J Infectious Dis,2020,91:264-266.
• [7] Zhou P,Yang XL,Wang XG,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020:1-4.
• [8] Zhao Y,Zhao Z,Wang Y,et al.Single-cell RNA expression profiling of ACE2,the putative receptor of Wuhan 2019-nCov[J].BioRxiv,2020.
• [9] Patel VB,Zhong JC,Grant MB,et al.Role of the ACE2/angiotensin 1-7 axis of the renin- angiotensin system in heart failure[J].Circ Res,2016,118(8):1313-1326.
• [10] Crackower MA,Sarao R,Oudit GY,et al.Angiotensin-converting enzyme 2 is anessential regulator of heart function[J].Nature,2002,417(6891):822-828.
• [11] Donoghue M,Hsieh F,Baronas E,et al.A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9[J].Circulation Res,2000,87(5):e1-e9.
• [12] Crackower MA,Sarao R,Oudit GY,et al.Angiotensin-converting enzyme 2 is an essential regulator of heart function[J].Nature,2002,417(6891):822-828.
• [13] Huentelman MJ,Zubcevic J,Prada JAH,et al.Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor[J].Hypertension,2004,44(6):903-906.
• [14] Imai M,Horiuchi M.Devil and angel in the renin-angiotensin system:ACE-angiotensin II-AT1 receptor axis vs.ACE2-angiotensin-(1-7)-Mas receptor axis[J].Hypertens Res,2009,32(7):533-536.
• [15] Simoes E Silva AC,Teixeira MM.ACE inhibition,ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis[J].Pharmacol Res,2016,107:154-162.
• [16] Tan W,Liao W,Zhou S,et al.Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases[J].Curr Opin Pharmacol,2018,40:9-17.
• [17] Gu H,Xie Z,Li T,et al.Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus[J].Sci Rep,2016,6:19840.
• [18] Li Y,Zeng Z,Li Y,et al.Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation[J].Shock,2015,43(4):395-404.
• [19] Fukushi S,Mizutani T,Saijo M,et al.Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein[J].J Gen Virol,2005,86(8):2269-2274.
• [20] Kuba K,Imai Y,Rao S,et al.A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J].Nat Med,2005,11(8):875-879.
• [21] Adedeji AO,Severson W,Jonsson C,et al.Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms[J].J Virol,2013,87(14):8017-8028.
• [22] Hoffmann M,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor[J].Cell,2020.[Epub ahead of print].
• [23] 高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,中国高血压防治指南修订委员会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):25.
• [24] 国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南[J].中国医学前沿杂志:电子版,2016,8(6):19-108.
• [25] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
• [26] 黎艳芳,关天旺,傅锐斌,等.肾素血管紧张素系统抑制剂对风湿性心脏病二尖瓣置换术患者的预后分析[J].实用医学杂志,2019,35(10):1590-1594.
• [27] Basu R,Poglitsch M,Yogasundaram H,et al.Roles of angiotensin peptides and recombinant human ACE2 in heart failure [J].J Am Coll Cardiol,2017,69(7):805-819.
• [28] Santos RAS,Sampaio WO,Alzamora AC,et al.The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system:focus on angiotensin-(1-7)[J].Physiol Rev,2018,98(1):505-553.
• [29] Xiao HL,Li CS,Zhao LX,et al.Captopril improves postresuscitation hemodynamics protective against pulmonary embolism by activating the ACE2/Ang-(1-7)/Mas axis[J].Naunyn Schmiedebergs Arch Pharmacol,2016,389(11):1159-1169.
• [30] Abuohashish HM,Ahmed MM,Sabry DC,et al.The ACE-2/Ang1-7/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade [J].Eur J Pharmacol,2017,807:44-55.
• [31] 刘靖.新型冠状病毒感染疫情防控期间做好血压管理,降压药物调整要科学、有据,不可盲目[J].中华高血压杂志,2020,28(3):201-203.
• [32] 李红芳,邓勇志.高血压患者感染新型冠状病毒:原用ACEI或ARB是否应继续使用 [J].临床心血管杂志,2020,36(3):204-208.
• [33] 翟利杰,王乔羽,赵志刚.血管紧张素转化酶2 受体及ACEI 或ARB 类药物与新型冠状病毒肺炎的相关性[J].医药导报,2020,39(5):633-636.